Trials & Tribulations Smoldering multiple myeloma: Rethinking the waiting game November 14, 2025Vol.51 No.42By C. Ola Landgren
Class action complaint alleging GRAIL insider fraud resubmitted after dismissal October 31, 2025Vol.51 No.40By Jacquelyn Cobb
Trials & Tribulations How GLP-1RA drugs are reshaping patient physiology and the future of oncology October 31, 2025Vol.51 No.40By Deborah Phippard
GRAIL to use new study results to seek FDA approval of Galleri MCD test October 24, 2025Vol.51 No.39By Jacquelyn Cobb
FreeTrials & Tribulations Experts warn that loss of carcinogen surveillance threatens to increase cancer incidence October 24, 2025Vol.51 No.39By David M. DeMarini, Rosalie Elespuru, Miriam C. Poirier and Errol Zeiger
Regulatory NewsTrials & Tribulations Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research October 17, 2025Vol.51 No.38By Edison T. Liu
Trials & Tribulations Earlier diagnosis, better outcomes: Telemedicine has found a home in oncology September 26, 2025Vol.51 No.35By Hardeep Phull
Conversation with The Cancer Letter Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out July 25, 2025Vol.51 No.29By Sara Willa Ernst, Jacquelyn Cobb and Paul Goldberg
First-ever financial toxicity tumor board aims to change the standard of careResearchers focus on debt as a side effect of cancer, treatment amid cuts to Medicaid, NCI July 11, 2025Vol.51 No.27By Claire Marie Porter
Trials & Tribulations An overlooked immune cell population may offer new direction for cell and gene therapy July 11, 2025Vol.51 No.27By Arthur Machlenkin
